Kyntra Bio, Inc. (KYNB) Financials

KYNB Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 101.1 million 109.2 million
March 31, 2026 109.6 million 140.4 million
Dec. 31, 2025 119.6 million 115.1 million
Sept. 30, 2025 137.0 million 119.5 million

KYNB Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -4.0 million 984000
March 31, 2026 -13.9 million 1.2 million
Dec. 31, 2025 -18.3 million 1.2 million
Sept. 30, 2025 -1.9 million 662000

KYNB Net Income

No data available :(

KYNB Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 91.3 million - -
March 31, 2026 87.2 million 19.2 million -
Dec. 31, 2025 89.0 million 19.6 million -
Sept. 30, 2025 118.0 million 19.5 million -

KYNB Shares Outstanding

No data available :(

KYNB Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 6.8 million 9.3 million -
March 31, 2026 - 7.6 million 5.9 million -
Dec. 31, 2025 - 7.3 million 8.0 million -
Sept. 30, 2025 9000 1.2 million 5.1 million -

KYNB Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 -1.5 million 2000
March 31, 2026 3.7 million 4.1 million
Dec. 31, 2025 1.3 million -463000
Sept. 30, 2025 1.1 million 134000

KYNB Revenue by Segment
Graph available only for paid members. Upgrade to see it.

KYNB

Price: $7.98

52 week price:
6.32
12.58

Earnings Per Share: -12.85 USD

P/E Ratio: -0.54

Exchange: NGM

Sector: Healthcare

Industry: Medical - Pharmaceuticals

Market Capitalization: 34.4 million

Links: